<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":3010,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/f0c4cbc06f0b4edece846c9eb719d2e0'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/f0c4cbc06f0b4edece846c9eb719d2e0'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HK5C0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HK5C0003">Previous Result: <span>In re Lewis, 471 Fed. Appx. 209 (4th Cir...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HK5C2003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HK5C2003">Next Result: <span>Johnson v. Ogletree, Deakins, Nash, Smoa...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation negative" title="Negative"></div>
<div class='title left' title='FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion'>
FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion</div>
<div class='docId'>X1HK3VM003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>FTC v. Watson Pharm., Inc.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1561</div>
<div class='displayCitation'>2012 BL 101301</div>
<div class='displayCitation'>677 F.3d 1298</div>
<div class='displayCitation'>bna a0d1q8q8a3</div>
<div class='displayCitation'>bna a0d1v7q5j7</div>
<div class='displayCitation'>wkf11case:26019835</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HK3VM003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="FTC v. Watson Pharm., Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HK3VM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HK3VM003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HK3VM003" /><input id="title" name="title" type="hidden" value="FTC v. Watson Pharm., Inc., 677 F.3d 1298, 102 U.S.P.Q.2d 1561 (11th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="NEGATIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="f0c4cbc06f0b4edece846c9eb719d2e0" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HK3VM003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Ff%30c%34cbc%30%36f%30b%34edece%38%34%36c%39eb%37%31%39d%32e%30%2Fdocument%2FX%31HK%33VM%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/bcite/X1HK3VM003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/bcite/X1HK3VM003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/bcite/X1HK3VM003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/related_content/X1HK3VM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1705235906563";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">677 F.3d 1298</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1561</div>
<div class="cite" data-cite-type="DocketNumber">10-12729</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 101301</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Eleventh Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
FEDERAL TRADE COMMISSION, Plaintiff-Counter Defendant-Appellant, v.
WATSON PHARMACEUTICALS, INC., Solvay Pharmaceuticals, Inc.,
Defendants-Appellees, Par Pharmaceutical Companies, Inc., Paddock
Laboratories, Inc., Defendants-Counter Claimants-Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-12729.
</center></p>
<p><center>
April 25, 2012.
</center></p>
<span CLASS="page_no" data-cite="677 f 3d 1299" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1299" data-primary-citation="677 F.3d 1298">[*1299]</span> <div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914047" href="#headnote_ref_pq2-dec_914047">[1]</a> <span>Patent misuse &mdash; Federal antitrust issues </span> <a href="http://www.bloomberglaw.com/document/1705235906563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=140.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="140.07">&#9658;140.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Settlement agreements; consent decrees </span> <a href="http://www.bloomberglaw.com/document/1705235906563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.43" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.43">&#9658;410.43</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Absent sham litigation or fraud in obtaining patent, &ldquo;reverse payment&rdquo; settlement of patent infringement litigation is immune from antitrust attack as long as its anticompetitive effects fall within scope of exclusionary potential of patent; in present case, allegation that owner of pharmaceutical patent was &ldquo;not likely to prevail&rdquo; in underlying infringement action against generic manufacturers does not sufficiently state antitrust claim, since such approach would improperly equate likely result with actual result, and proper focus is on potential exclusionary effect of patent, not likely exclusionary effect, since risks involved in patent litigation provide motivation to settle for both sides, not just side that is likely to lose, since approach that employs after-the-fact calculation of how &ldquo;likely&rdquo; patent holder was to succeed in lawsuit is too uncertain to serve as basis for antitrust liability and treble damages, would impose heavy burdens on parties and courts, and is unlikely to be reliable, and since nonspecialized circuit courts are ill-equipped to make judgments about merits of patent infringement claims.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="677 f 3d 1300" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1300" data-primary-citation="677 F.3d 1298">[*1300]</span> 
</p></div></div>
<div id="para2" printdualcolumn="true"><p>
  Imad Dean Abyad, Bradley S. Albert, John F. Daly, Markus H.
Meier, John R. Robertson, Mark J. Woodward, FTC, Office of Gen.
Counsel, Lore A. Unt, U.S. FTC, Washington, DC, Cindy A.
Liebes, FTC, Atlanta, GA, for Plaintiff-Appellant.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Jason W. Eakes, David A. Rabin, Morris, Manning &amp; Martin,
LLP, Mark Gerald Trigg, Greenberg Traurig, LLP, Teresa Thebaut
Bonder, Matthew Kent, Alston &amp; Bird, LLP, Atlanta, GA,
Maris A. Raptis, Skadden, Arps, Slate, Meagher &amp; Flom, LLP,
New York City, Steven Craig Sunshine, Julia K. York, Skadden,
Arps, Slate, Meagher &amp; Flom, LLP, J. Mark Gidley, Eric
Grannon, White &amp; Case, LLP, John Roberti, Rebecca
Valentine, Mayer Brown, LLP, Washington, DC, Jeffrey I.
Weinberger, Munger, Tolles &amp; Olson, LLP, Los Angeles, CA,
Rohit K. Singla, Munger, Tolles &amp; Olsen, LLP, San
Francisco, CA, for Defendants-Appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
Northern District of Georgia.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before CARNES, KRAVITCH, and FARRIS,<a HREF="#fn*00" name="fnref_fn*00">[fn*]</a> Circuit Judges.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn*00" name="fn*00">[fn*]</a></span> Honorable Jerome Farris, United States Circuit Judge for
the Ninth Circuit, sitting by designation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CARNES, Circuit Judge:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The system of developing new drugs in this country
exemplifies the maxims "no risk, no reward" and "more risk,
more reward." Developing new drugs is a risky, lengthy, and
costly endeavor, but it also can be highly lucrative. Only one
in every 5,000 medicines tested for the potential to treat
illness is eventually approved for patient use, and studies
estimate that developing a new drug takes 10 to 15 years and
costs more than $1.3 billion.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> No rational actor would take
that kind of a risk <span CLASS="page_no" data-cite="102 uspq 2d 1562" data-cite-type="ReporterOfDecisions" data-cite-pageno="1562" data-primary-citation="102 U.S.P.Q.2d 1561">[**1562]</span> over that period of time without the
prospect of a big reward. The reward, if any, comes when the
drug is approved and patented, giving the pioneer or "brand
name" company that developed it a monopoly over the sale of the
new drug for the life of the patent. The pioneer company can
then exploit the patent monopoly by charging higher prices than
it could if competitors were allowed to sell bioequivalent or
"generic" versions of the drug. In that manner, the pioneer
company is usually able to recoup its investment and gain a
profit, sometimes a super-sized one.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Another maxim might also apply to the patent monopoly of drug
pioneers: "more money, more problems." The huge profits that
new drugs can bring frequently attract competitors in the form
of generic drug manufacturers that challenge or try to
circumvent the pioneer's monopoly in the market. Patent
litigation often results, threatening the pioneer's monopoly
and profits. Instead of rolling the dice and risking their
monopoly profits in the infamously costly and notoriously
unpredictable process of patent litigation, many patent-holding
companies choose to settle
<span CLASS="page_no" data-cite="677 f 3d 1301" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1301" data-primary-citation="677 F.3d 1298">[*1301]</span> 
lawsuits in order to preserve their patents and keep the
<span CLASS="page_no" data-cite="2012 bl 101301 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> monopoly profits flowing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case involves a type of patent litigation settlement known
as a "pay for delay" or "reverse payment" agreement. In this
type of settlement, a patent holder pays the allegedly
infringing generic drug company to delay entering the market
until a specified date, thereby protecting the patent monopoly
against a judgment that the patent is invalid or would not be
infringed by the generic competitor. This case began when the
Federal Trade Commission filed a complaint in district court
alleging that the reverse payment settlements between the
holder of a drug patent and two generic manufacturers of the
drug are unfair restraints on trade that violate federal
antitrust laws. The FTC claims that the settlements are simply
tools that the three manufacturers used to avoid a judgment
that the patent was invalid or would not be infringed by the
generics, thereby protecting monopoly profits that the
companies divvied up by means of payments from the patent
holder to the generic manufacturers. The key allegation in the
FTC's complaint is that the patent holder was "not likely to
prevail" in the infringement actions that it brought against
the generic manufacturers and then settled. According to the
FTC, the reverse payment settlements unlawfully protected or
preserved a monopoly that likely was invalid and that should
not be shielded from antitrust attack.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The drug companies counter that, far from being devices
designed to dodge antitrust restrictions, reverse payment
settlements are simply a way that patent holders protect and
maintain the lawful exclusionary rights patent law grants them.
<i>Cf. Walker Process Equip., Inc. v. Food Mach &amp; Chem.</i>
<i>Corp.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C6BD?jcsearch=382%20us%20172&amp;summary=yes#jcite">382 U.S. 172</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C6BD?jcsearch=382%20us%20172&amp;summary=yes#jcite">177</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C6BD?jcsearch=86%20supreme%20court%20347&amp;summary=yes#jcite">86 S.Ct. 347</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C6BD?jcsearch=86%20supreme%20court%20347&amp;summary=yes#jcite">350</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C6BD?jcsearch=15%20l%20ed%202d%20247&amp;summary=yes#jcite">15 L.Ed.2d 247</a> (1965) ("A patent . . . is an exception to the general
rule against monopolies. . . ." (quotation marks omitted));
<i>Precision Instrument Mfg. Co. v. Auto. Maint. Mach</i>
<i>Co.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0S5?jcsearch=324%20us%20806&amp;summary=yes#jcite">324 U.S. 806</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0S5?jcsearch=324%20us%20806&amp;summary=yes#jcite">816</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0S5?jcsearch=65%20supreme%20court%20993&amp;summary=yes#jcite">65 S.Ct. 993</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0S5?jcsearch=65%20supreme%20court%20993&amp;summary=yes#jcite">998</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0S5?jcsearch=89%20l%20ed%201381&amp;summary=yes#jcite">89 L.Ed. 1381</a>
(1945) (same). They say that punishing a patent holder for
paying a potential competitor to stay out of the market as
part of a settlement agreement would penalize precisely what patents
are designed to permit: the exclusion of competition. That
erosion of patent rights, the drug companies argue, would
weaken incentives for investing in drug development, which
would reduce the number of life-saving or life-enhancing
innovations that benefit consumers.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC would like us to hold that reverse payment settlements,
like the ones in this case, are presumptively unlawful
restraints of trade. It argues that such settlements allow
brand name and generic drug companies to be partners in
unlawful monopolies. Monopoly profits, the FTC says, will
typically exceed the sum of the individual profits that the
drug companies could make by competing against each other. So
even if the generic drug company is likely to win the
infringement suit, it has a strong economic incentive to drop
its lawsuit in exchange for a share of the brand name company's
monopoly profits.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
<span CLASS="page_no" data-cite="677 f 3d 1302" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1302" data-primary-citation="677 F.3d 1298">[*1302]</span> 
Viewed <span CLASS="page_no" data-cite="102 uspq 2d 1563" data-cite-type="ReporterOfDecisions" data-cite-pageno="1563" data-primary-citation="102 U.S.P.Q.2d 1561">[**1563]</span> this way, a reverse payment settlement ending patent
litigation is a "win-win" for both companies. The brand name
drug company maintains <span CLASS="page_no" data-cite="2012 bl 101301 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> its monopoly by enforcing a patent that
may be invalid, and the generic drug company makes more money
under the settlement than it could have earned by competing in
a market free of the patent's restraints. While the drug
companies are the big winners in this scenario, consumers are
the big losers; they continue paying monopoly prices for the
drug even though the patent creating the monopoly is likely
invalid or would not be infringed by generic competition. The
FTC estimates that reverse payment settlements cost consumers
about $3.5 billion per year in the form of higher drug prices.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The usual protocol in opinions is to put the facts and
procedural history of the case before a discussion of the
applicable statutes, but in this case the facts make more sense
after a discussion of the statutory process for introducing new
drugs to the market.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  No one can legally market or sell a new drug in the United
States without first gaining the approval of the Food and Drug
Administration. <i>See</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(a). The
particular pathway to approval depends largely on the type of
drug involved. One pathway is for pioneer drugs, which are ones
that have never before received FDA approval. To initiate that
approval process, an applicant files a New Drug Application.
<i>See <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(a)&amp;summary=yes#jcite">id</a>.</i> The NDA must contain detailed information about
the drug, including its chemical composition, "full reports of
investigations" about its safety and efficacy, descriptions of
its production and packaging processes, and proposed labeling
language. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">Id. &sect; 355(b)(1)</a>. An NDA applicant must
also provide the FDA with "the patent number and the expiration
date of any patent" that a generic manufacturer would infringe
by making or selling the applicant's drug. <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">Id</a>; see</i>
<i>also</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XMJ52O003?jcsearch=21%20C.F.R.%20%20314.53(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.53</a>(b). If the FDA approves the
NDA, it publishes the drug and patent information in a book
called "Approved Drug Products with Therapeutic Equivalence and
Evaluations," commonly referred to as the "Orange Book."
<i>See</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(7)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(7)(A); <i>see also Caraco</i>
<i>Pharm. Labs., Ltd. v. Novo Nordisk AIS</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=132%20S.Ct.%201670&amp;summary=yes#jcite">___ U.S. ___</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">132 S.Ct. 1670</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">1675-76</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=USCASE%20___%20L.Ed.2d%20___&amp;summary=yes#jcite">___ L.Ed.2d ___</a> (2012). The pioneer
company may then market and sell the drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A more streamlined pathway to approval is reserved for generic
versions of pioneer drugs that the FDA has already approved and
listed in the Orange Book. To begin the generic drug approval
process, an applicant files an Abbreviated New Drug
Application. <i>See</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j). The ANDA
allows an applicant "to piggyback on the safety and efficacy
studies conducted for the pioneer drug" and thereby gain FDA
approval by establishing that the generic drug is chemically
identical to a pioneer drug already listed in the Orange Book.
<i>Valley Drug Co. v. Geneva Pharm., Inc.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d 1294</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">1296</a> (11th Cir. 2003); <i>see</i>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A); <i>Caraco Pharm. Labs.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">132 S.Ct. at 1676</a>
("Rather than providing independent evidence of safety and
efficacy, the typical ANDA shows that the generic drug has the
same
<span CLASS="page_no" data-cite="677 f 3d 1303" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1303" data-primary-citation="677 F.3d 1298">[*1303]</span> 
active ingredients as, and is biologically equivalent to,
the brand-name drug.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An ANDA that piggybacks on a drug listed in the Orange Book
must make one of four "paragraph certifications" with respect
to any patents affiliated with the listed drug. It must certify
that: (I) no patent information for the brand name drug <span CLASS="page_no" data-cite="2012 bl 101301 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> has
been filed with the FDA; (II) the patent has expired; (III) the
patent will expire on a specifically identified date; or (IV)
the "patent is invalid or will not be infringed by the
manufacture, use, or sale of the new drug for which the
application is submitted." <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It matters which certification is made. If the applicant
certifies under paragraphs I or II, the FDA reviews the ANDA
and may approve it. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(i)&amp;summary=yes#jcite">id. &sect; 355(j)(5)(B)(i)</a>. If
the applicant certifies under paragraph III, however, the FDA
will not approve the application until the patent for the
listed drug has expired. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(ii)&amp;summary=yes#jcite">id.
&sect; 355(j)(5)(B)(ii)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If the applicant certifies under paragraph IV, things get
complicated. The ANDA applicant must send notice to the patent
holder of its position <span CLASS="page_no" data-cite="102 uspq 2d 1564" data-cite-type="ReporterOfDecisions" data-cite-pageno="1564" data-primary-citation="102 U.S.P.Q.2d 1561">[**1564]</span> that the patent listed in the Orange
Book is invalid or will not be infringed by the applicant's
generic drug. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(B)&amp;summary=yes#jcite">id. &sect; 355(j)(2)(B)</a>. The patent
holder then has 45 days to file an infringement lawsuit against
the ANDA applicant. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)&amp;summary=yes#jcite">Id. &sect; 355(j)(5)(B)(iii)</a>;
<i>cf.</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A) (making it a
constructive act of infringement to file a
paragraph IV certification); <i>Cameo Pharm. Labs.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">132 S.Ct. at 1677</a> ("Filing a paragraph IV certification
means provoking litigation."). If the patent holder does not
sue within that time frame, the FDA proceeds with the ANDA
approval process. <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iii). If a suit
is timely filed, however, the FDA stays the ANDA approval
process for 30 months to allow the parties or a court to
resolve the infringement dispute. <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)&amp;summary=yes#jcite">Id</a>.</i> If, during that
30-month stay, a court decides that the patent is invalid or
not infringed, the FDA's approval of the ANDA, if any, is
effective on the date that the court enters its judgment.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)(I)(aa)&amp;summary=yes#jcite">Id. &sect; 355(j)(5)(B)(iii)(I)(aa)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Federal law encourages generic drug manufacturers to file
paragraph IV certifications. The first ANDA applicant making a
paragraph IV certification that receives FDA approval
is granted a 180-day "exclusivity period" during which the FDA
postpones its approval process for other ANDA applications for
generic versions of the same Orange Book listed drug.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)&amp;summary=yes#jcite">Id. &sect; 355(j)(5)(B)(iv)</a>. That exclusivity period
begins to run "after the date of the first commercial marketing
of the [generic] drug." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.355(j)(5)(B)(iv)(I)&amp;summary=yes#jcite">Id. &sect; 355(j)(5)(B)(iv)(I)</a>;
<i>see also</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XMJ54G003?jcsearch=21%20C.F.R.%20%20314.107(c)(1)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.107</a>(c)(1). As a result,
the first generic manufacturer to make a paragraph IV
certification could receive a 180-day head start to compete
with the pioneer drug, which is "a significant incentive for
generic manufacturers to challenge weak or narrow drug
patents." <i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1298</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With that statutory approval process in mind, we turn to the
facts of this case. Because this appeal arises from the
district court's Rule 12(b)(6) dismissal of the FTC's complaint
for failure to state a claim, we accept as true all of the
factual allegations in that complaint. <i>Thaeter v. Palm</i>
<i>Beach Cnty. Sheriff's Office</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X153OOI003?jcsearch=449%20f%203d%201342&amp;summary=yes#jcite">449 F.3d 1342</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X153OOI003?jcsearch=449%20f%203d%201342&amp;summary=yes#jcite">1352</a> (11th
Cir. 2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>A.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Besins Healthcare, S.A., developed the prescription drug
AndroGel, a topical gel that treats the symptoms of low
testosterone in men. Chemicals in the gel gradually
<span CLASS="page_no" data-cite="677 f 3d 1304" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1304" data-primary-citation="677 F.3d 1298">[*1304]</span> 
penetrate the skin and enter the blood-stream, providing a
sustained release of synthetic testosterone. In August 1995,
Besins granted Solvay Pharmaceuticals, Inc., a license to sell
AndroGel in the United States and agreed to provide a
commercial supply of the drug if the FDA approved <span CLASS="page_no" data-cite="2012 bl 101301 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> it for sale.
Solvay filed an NDA for AndroGel in April 1999, which the FDA
approved in February 2000. Solvay then began marketing and
selling the drug with great success. Between 2000 and 2007,
revenue from the sale of AndroGel in the United States exceeded
$1.8 billion, far more than it cost to develop the drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Shortly after the FDA approved AndroGel, Solvay filed a patent
application with the Patent and Trademark Office. A prior
patent covering the synthetic testosterone used in AndroGel had
expired decades earlier, but Solvay's application sought patent
protection for a particular gel formulation of it. The Patent
and Trademark Office granted Solvay's application on January 7,
2003, and jointly awarded Solvay and Besins <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">Patent Number
6,503,894</a> ("the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a>"), which expires in August 2020.
Within 30 days of being granted the patent, Solvay asked the
FDA to include the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a> information in the Orange Book
alongside the AndroGel listing. <i>Cf.</i>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(c)(2)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(c)(2) (requiring successful NDA applicants to inform the
FDA within 30 days of receiving a new patent for a listed
drug).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Other drug manufacturers soon developed generic versions of
AndroGel. Two of those companies, Watson Pharmaceuticals, Inc.
and Paddock Laboratories, Inc., filed ANDAs with the FDA in May
2003. Watson was the first to file its ANDA, which made it
eligible for the 180-day exclusivity period under
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv). Both companies made paragraph IV
certifications, claiming that their generic AndroGel products
did not infringe on the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a> or that the patent was
invalid. Within the relevant 45-day window, <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)&amp;summary=yes#jcite">id.
&sect; 355(j)(5)(B)(iii)</a>, Solvay filed in federal district court a
patent infringement lawsuit <span CLASS="page_no" data-cite="102 uspq 2d 1565" data-cite-type="ReporterOfDecisions" data-cite-pageno="1565" data-primary-citation="102 U.S.P.Q.2d 1561">[**1565]</span> against Watson and Paddock.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
That filing triggered the 30-month stay of the FDA's approval
process for Watson's and Paddock's generic versions of
AndroGel. <i>See <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)&amp;summary=yes#jcite">id</a>.</i> The stay was set to expire in
January 2006.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties litigated the infringement action for the next few
years. To spread the risks and costs of litigation, Paddock
partnered with Par Pharmaceutical Companies, Inc., which agreed
to share the costs of litigation with Paddock in exchange for
part of the potential profits from Paddock's generic AndroGel
product if that product gained FDA approval. After conducting
discovery, Watson and Par/Paddock, the defendants in the patent
infringement lawsuit, filed motions for summary judgment on the
validity of the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a>. Those motions were fully briefed
and ready for decision when the statutorily imposed 30-month
stay on the FDA's approval process for Watson's ANDA ended in
January 2006. The FDA approved Watson's generic AndroGel
product that same month.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As a result, Solvay was facing the possibility of losing its
monopoly in the AndroGel market in early 2006. If the district
court granted Watson's motion for summary judgment either on
the ground that the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a> was invalid or that it would
not be infringed by the generic drugs, Watson could immediately
flood the market with generic versions of AndroGel
<span CLASS="page_no" data-cite="677 f 3d 1305" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1305" data-primary-citation="677 F.3d 1298">[*1305]</span> 
without fear of being found to have violated Solvay's
patent (unless the district court's decision was overturned on
appeal). <i>See</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iii)(I)(aa)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iii)(I)(aa).
Watson forecast that <span CLASS="page_no" data-cite="2012 bl 101301 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> its generic version of AndroGel would sell
for about 25% of the price of branded AndroGel, which could
decrease the sales of branded AndroGel by 90% and cut Solvay's
profits by $125 million per year. A lot was riding on the
outcome of the patent litigation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Before the district court ruled on Watson's and Par/Paddock's
motions for summary judgment, and before any generic AndroGel
was brought to market, the parties resolved their patent
dispute with several settlement agreements. Under the terms of
the settlements, Watson, Par, and Paddock agreed not to market
generic versions of AndroGel until August 31, 2015, unless
another manufacturer launched one before then. In addition,
Watson agreed to promote branded AndroGel to urologists, and
Par agreed to promote it to primary care doctors. Par also
agreed to serve as a backup manufacturer for branded AndroGel
but assigned that part of the agreement to Paddock.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For its part, Solvay agreed to pay Par/Paddock $10 million per
year for six years and an additional $2 million per year for
the backup manufacturing assistance. Solvay also agreed to
share some of its AndroGel profits with Watson through
September 2015, projecting that those payments would be between
$19 million and $30 million per year. After finalizing the
agreements, all of the parties &mdash; Solvay, Watson, Par, and
Paddock &mdash; filed in district court a stipulation of
dismissal terminating the patent infringement lawsuit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>B.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After the settlement agreements ending the patent litigation
were reported to the FTC as required by <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/1?citation=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>
note (2003) (Federal Trade Commission Review), the FTC filed an
antitrust lawsuit against Solvay, Watson, Par, and Paddock.
That lawsuit was then transferred to the Northern District of
Georgia, which is where the parties had litigated the patent
infringement claims. The FTC then filed an amended complaint
against all four drug companies.<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC's amended complaint claimed that the settlement
agreements, in which Solvay promised to pay Watson and
Par/Paddock in exchange for those companies not selling generic
AndroGel until 2015, are unlawful agreements not to compete in
violation of <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEHDR8003?jcsearch=15%20U.S.C.%20%2045(a)(1)&amp;summary=yes#jcite">Section 5(a)</a> of the Federal Trade Commission Act.
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEHDR8003?jcsearch=15%20U.S.C.%20%2045(a)(1)&amp;summary=yes#jcite">15 U.S.C. &sect; 45</a>(a)(1) (banning "[u]nfair methods of
competition in or affecting commerce, and unfair or deceptive
acts or practices in or affecting commerce"). It alleged that
the settlement agreements were attempts to "defer" generic
competition with branded AndroGel by postponing the entry date
of the generic drugs, thereby maintaining Solvay's monopoly and
allowing the parties to share monopoly profits "at the expense
of the consumer savings that would result from price
competition."
<span CLASS="page_no" data-cite="102 uspq 2d 1566" data-cite-type="ReporterOfDecisions" data-cite-pageno="1566" data-primary-citation="102 U.S.P.Q.2d 1561">[**1566]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The lynchpin of the FTC's complaint is its allegation that
Solvay probably would have lost the underlying patent
infringement action &mdash; that is, Watson and Par/Paddock had
a strong case that the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a> did not bar their entry into
the generic AndroGel market. More specifically, the complaint
alleges that "Solvay was <i>not likely to prevail</i>" in the
patent litigation because "Watson and Par/Paddock developed
<span CLASS="page_no" data-cite="677 f 3d 1306" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1306" data-primary-citation="677 F.3d 1298">[*1306]</span> 
persuasive arguments <span CLASS="page_no" data-cite="2012 bl 101301 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> and amassed substantial evidence that
their generic products did not infringe the [`894] patent and
that the patent was invalid and/or unenforceable" (emphasis
added). According to the FTC, because the `894 patent "was
unlikely to prevent generic entry," Solvay's reverse payments
to the generic drug producers continued and extended a monopoly
that the patent laws did not authorize. By doing that, it
argues, the reverse payment agreements unlawfully restrain
competition.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The four defendants moved to dismiss the FTC's complaint under
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">Rule 12(b)(6)</a>, arguing that this Court's precedent immunizes
reverse payment settlements from antitrust attack unless a
settlement "imposes an exclusion greater than that contained in
the patent at issue." Because the FTC had not alleged the
settlements did that, the defendants argued, the complaint
failed to state a claim on which relief could be granted. The
district court agreed with the defendants, concluded that the
FTC did "not allege that the settlements exceed the scope of
the `<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3180684H0J?jcsearch=usp%206503894&amp;summary=yes#jcite">894 patent</a>," and granted the defendants' motion to
dismiss. The FTC then filed this appeal, contending that it had
sufficiently pleaded an antitrust claim by alleging that the
parties had entered into the settlement agreements even though
Solvay was "not likely to prevail" in the infringement actions
against the generic producers.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  <b>III.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "We review <i>de novo</i> the district court's grant of a
motion to dismiss under <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">12(b)(6)</a> for failure to state a claim. . . ."
<i>Ironworkers Local Union 68 v. AstraZeneca Pharm.,</i>
<i>LP</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1F3SPU003?jcsearch=634%20f%203d%201352&amp;summary=yes#jcite">634 F.3d 1352</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1F3SPU003?jcsearch=634%20f%203d%201352&amp;summary=yes#jcite">1359</a> (11th Cir. 2011) (quotation marks
omitted). In doing so, we accept the allegations in the
complaint as true and construe them "in the light most
favorable to the plaintiff." <i>Clark v. Riley</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1CFUEC003?jcsearch=595%20f%203d%201258&amp;summary=yes#jcite">595 F.3d 1258</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1CFUEC003?jcsearch=595%20f%203d%201258&amp;summary=yes#jcite">1264</a> (11th Cir. 2010) (quotation marks omitted). "A
complaint must state a plausible claim for relief, and `[a]
claim has facial plausibility when the plaintiff pleads factual
content that allows the court to draw the reasonable inference
that the defendant is liable for the misconduct alleged.'"
<i>Sinaltrainal v. Coca-Cola Co.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1BFDES003?jcsearch=578%20f%203d%201252&amp;summary=yes#jcite">578 F.3d 1252</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1BFDES003?jcsearch=578%20f%203d%201252&amp;summary=yes#jcite">1261</a>
(11th Cir. 2009) (quoting <i>Ashcroft v. Iqbal</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1B3QVK003?jcsearch=556%20us%20662&amp;summary=yes#jcite">556 U.S. 662</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1B3QVK003?jcsearch=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. 1937</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1B3QVK003?jcsearch=129%20supreme%20court%201937&amp;summary=yes#jcite">1949</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1B3QVK003?jcsearch=173%20l%20ed%202d%20868&amp;summary=yes#jcite">173 L.Ed.2d 868</a> (2009)) (alteration
in <i>Sinaltrainal</i>). "Stated differently, the factual
allegations in a complaint must `possess enough heft' to set
forth `a plausible entitlement to relief. . . ." <i>Fin. Sec.</i>
<i>Assurance, Inc. v. Stephens, Inc.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17MD52003?jcsearch=500%20f%203d%201276&amp;summary=yes#jcite">500 F.3d 1276</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17MD52003?jcsearch=500%20f%203d%201276&amp;summary=yes#jcite">1282</a>
(11th Cir. 2007) (quoting <i>Bell Atl. Corp. v. Twombly</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. 544</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">557</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">559</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=127%20supreme%20court%201955&amp;summary=yes#jcite">1966-57</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X17292G003?jcsearch=167%20l%20ed%202d%20929&amp;summary=yes#jcite">167 L.Ed.2d 929</a> (2007)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>A.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The difficulty at the heart of this case is in deciding how to
resolve the tension between the pro-exclusivity tenets of
patent law and the pro-competition tenets of anti-trust law.
That difficulty is made less difficult, however, by the law's
pro-precedent tenets. Our earlier decisions carry us much of
the way to a resolution in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This Court first confronted an antitrust challenge to a reverse
payment settlement in <i>Valley Drug Co. v. Geneva</i>
<i>Pharmaceuticals, Inc.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d 1294</a> (11th Cir. 2003). The
facts of that case parallel the facts of this one: Two generic
manufacturers alleged that the patent for a drug listed in the
Orange Book was invalid, the patent holder filed infringement
claims against the generic manufacturers, and the parties
settled before a court decided the merits <span CLASS="page_no" data-cite="2012 bl 101301 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> of the claims.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1298-300</a>. One generic manufacturer received
millions of dollars in exchange for acknowledging the validity
<span CLASS="page_no" data-cite="677 f 3d 1307" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1307" data-primary-citation="677 F.3d 1298">[*1307]</span> 
of the pioneer's patent and agreeing not to enter the
market until another generic manufacturer did or until the
patent expired, whichever came first. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1300</a>. The
other generic manufacturer, also in exchange for millions of
dollars, agreed not to enter the market until one of those two
events occurred or until a court held that the patent was
invalid, whichever came first. <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Several private parties filed an antitrust lawsuit against the
three manufacturers alleging that the settlement agreements
were per se illegal contracts in restraint of trade in
violation of <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEHDNG003?jcsearch=15%20U.S.C.%20%201&amp;summary=yes#jcite">Section 1</a> of the Sherman Act.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> <i>See</i>
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">id. at 1295-96</a>; <i>see also</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEHDNG003?jcsearch=15%20usc%201&amp;summary=yes#jcite">15 U.S.C. &sect; 1</a>
("Every <span CLASS="page_no" data-cite="102 uspq 2d 1567" data-cite-type="ReporterOfDecisions" data-cite-pageno="1567" data-primary-citation="102 U.S.P.Q.2d 1561">[**1567]</span> contract . . . in restraint of trade or commerce among
the several States, or with foreign nations, is declared to be
illegal."). The district court agreed with the plaintiffs and
granted their motion for partial summary judgment. <i>See</i>
<i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1295</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">1301</a>. After the court
granted the drug companies' request for permission to take an
interlocutory appeal, <i>see</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEIMUA003?jcsearch=28%20U.S.C.%20%201292(b)&amp;summary=yes#jcite">28 U.S.C. &sect; 1292</a>(b), we
reversed. <i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1295</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">1313</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our <i>Valley Drug</i> decision began by acknowledging that
antitrust laws typically prohibit agreements where one company
pays a potential competitor not to enter the market, but we
reasoned that reverse payment settlements of patent litigation
presented atypical cases because "one of the parties own[s] a
patent." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1304</a>. The patent made all the
difference because it meant that the patent holder had a
"lawful right to exclude others" from the market. <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id</a>.; see</i>
<i>also</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEJ01G003?jcsearch=35%20U.S.C.%20%20154(a)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 154</a>(a)(1) ("Every patent shall . . .
grant to the patentee . . . the right to exclude others from
making, using, offering for sale, or selling the invention
throughout the United States. . . ."); <i>Dawson Chem. Co.</i>
<i>v. Rohm &amp; Haas Co.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CA04?jcsearch=448%20us%20176&amp;summary=yes#jcite">448 U.S. 176</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CA04?jcsearch=448%20us%20176&amp;summary=yes#jcite">215</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CA04?jcsearch=100%20supreme%20court%202601&amp;summary=yes#jcite">100 S.Ct. 2601</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CA04?jcsearch=100%20supreme%20court%202601&amp;summary=yes#jcite">2623</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CA04?jcsearch=65%20l%20ed%202d%20696&amp;summary=yes#jcite">65 L.Ed.2d 696</a> (1980) ("[T]he essence of a patent grant
is the right to exclude others from profiting by the patented
invention."). The district court, we explained, "failed to
consider" those exclusionary rights in its antitrust analysis
when it held that the agreements were per se illegal.
<i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1306</a>. Because one party to
the reverse payment agreements held a patent, the agreements
did not necessarily decrease the level of competition in the
market. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1309</a>. It followed that the district
court had erred in using a per se test for determining the
legality of the agreements. <i>See <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">id</a>.</i> ("If [the patent
holder] had a lawful right to exclude competitors, it is not
obvious that competition was limited more than that lawful
degree by paying potential competitors for their exit.");
<i>see also Schering-Plough Corp. v. FTC</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d 1056</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">1065-66</a> (11th Cir. 2005) ("By their nature, patents create an
environment of exclusion, and consequently, cripple
competition. The anticompetitive effect is already present.");
<i>cf. Asahi Glass Co. v. Pentech Pharm., Inc.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6B5O7?jcsearch=289%20f%20supp%202d%20986&amp;summary=yes#jcite">289 F.Supp.2d 986</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6B5O7?jcsearch=289%20f%20supp%202d%20986&amp;summary=yes#jcite">994</a> (N.D.111.2003) (Posner, J., sitting by
designation) ("In a reverse-payment case, the settlement leaves
the competitive situation unchanged from before the [generic
manufacturer] tried to enter the market.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After deciding to reverse the district court's partial grant of
summary judgment in favor of the plaintiffs in <i>Valley</i>
<i>Drug</i>, we went on to discuss several <span CLASS="page_no" data-cite="2012 bl 101301 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> other matters
<span CLASS="page_no" data-cite="677 f 3d 1308" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1308" data-primary-citation="677 F.3d 1298">[*1308]</span> 
"that promise[d] to be relevant on remand." <i>Valley</i>
<i>Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1306</a>. We first addressed the plaintiffs'
argument that the analysis on remand should disregard the
patent altogether because after the parties had entered into
their settlement agreements a federal district court had
invalidated the patent at issue. According to the plaintiffs in
<i>Valley Drug</i>, that post-settlement invalidation meant
the patent holder "never had any patent rights," which meant
the settlements necessarily excluded more competition from the
market than the patent holder was lawfully entitled to exclude
(namely, none). <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1306-07</a>. Which meant, according
to the plaintiffs, there were no patent rights to shield the
settlements from antitrust attack, which meant the settlements
were "subject to <i>per se</i> condemnation." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id.
at 1306</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We rejected that argument, explaining that a court must judge
the antitrust implications of a reverse payment settlement as
of the time that the settlement was executed. <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id</a>.</i>
"[T]he mere subsequent invalidity of the patent does not render
the patent irrelevant to the appropriate antitrust analysis."
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1306-07</a>. For that reason, even though the
patent at issue in <i>Valley Drug</i> was in fact invalid,
its terms had to be given full effect. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">id. at 1305</a>
(explaining that, at the time of settlement, the patent holder
had "the right to exclude others from making, using, or selling
anhydrous terazosin hydrochloride until October of 2014, when
[the patent] is due to expire").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our decision to give full effect to the patent's terms in
<i>Valley Drug</i> means that even a court judgment about a
patent's <i>actual</i> exclusionary power, unless that
judgment comes before settlement, does not count. What does
count is the patent's "<i>potential</i> exclusionary power"
as it appeared at the time of settlement. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1311</a>
(emphasis added). The patent in <i>Valley Drug</i> had the
potential to exclude competition at the time of settlement
because, <span CLASS="page_no" data-cite="102 uspq 2d 1568" data-cite-type="ReporterOfDecisions" data-cite-pageno="1568" data-primary-citation="102 U.S.P.Q.2d 1561">[**1568]</span> at that time, "no court had declared [the] patent
invalid." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1306</a>; <i>cf.</i>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a> ("A patent shall be presumed valid."). Because the patent
had that potential at the time of settlement, we treated the
holder as though it had an exclusionary right at that time.
<i>See Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1306</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our discussion in <i>Valley Drug</i> about the "potential
exclusionary power" of patents did not mean, however, that all
reverse payment settlements of patent litigation are immune
from antitrust attack. A patent holder and any of its
challengers cannot enter into an agreement that excludes more
competition than the patent has the potential to exclude. If a
reverse payment settlement reduces generic competition to a
greater extent than the patent grant potentially does, the
holder of the patent has used the settlement to buy
exclusionary rights that are not contained in the patent grant,
and those additional rights are vulnerable to antitrust attack.
<i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">id. at 1312</a> ("[T]he patent exception to antitrust
liability . . . is limited by the terms of the patent and the
statutory rights granted the patentee."); <i>cf. United States</i>
<i>v. Masonite Corp.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0EM?jcsearch=316%20us%20265&amp;summary=yes#jcite">316 U.S. 265</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0EM?jcsearch=316%20us%20265&amp;summary=yes#jcite">277</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0EM?jcsearch=62%20supreme%20court%201070&amp;summary=yes#jcite">62 S.Ct. 1070</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0EM?jcsearch=62%20supreme%20court%201070&amp;summary=yes#jcite">1077</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C0EM?jcsearch=86%20l%20ed%201461&amp;summary=yes#jcite">86 L.Ed. 1461</a> (1942) ("The owner of a patent cannot extend his
statutory grant by contract or agreement. A patent affords no
immunity for a monopoly <span CLASS="page_no" data-cite="2012 bl 101301 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> not fairly or plainly within the
grant."). Put another way, a patent gives its holder a "bundle
of rights," <i>CMS Indus., Inc. v. L.P.S. Int'l Ltd.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3P8JS?jcsearch=643%20f%202d%20289&amp;summary=yes#jcite">643 F.2d 289</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X3P8JS?jcsearch=643%20f%202d%20289&amp;summary=yes#jcite">294</a> (5th Cir. 1981), <a HREF="#fn600" name="fnref_fn600">[fn6]</a> but any new exclusionary
rights
<span CLASS="page_no" data-cite="677 f 3d 1309" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1309" data-primary-citation="677 F.3d 1298">[*1309]</span> 
the holder buys to add to that bundle do not fall within
the scope of the patent grant and for that reason do not fall
within the scope of the patent's antitrust immunity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In keeping with those principles, we said in <i>Valley</i>
<i>Drug</i> that parties to a reverse payment settlement are
immune from antitrust liability if the anticompetitive effects
of their settlement fall "within the scope of the exclusionary
potential of the patent." <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1311</a>. If any provisions
of the settlement create restraints on competition beyond that
scope, however, those excesses "may then be subject to
traditional antitrust analysis to assess their probable
anticompetitive effects in order to determine whether [they]
violate <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEHDNG003?jcsearch=15%20U.S.C.%20%201&amp;summary=yes#jcite">&sect; 1</a> of the Sherman Act."<a HREF="#fn700" name="fnref_fn700">[fn7]</a> <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id. at 1312</a>.
What was left for the district court to do on remand was to
consider "the scope of the exclusionary potential of the patent
[and] the extent to which the[] provisions of the Agreements
exceed that scope." <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20F.3d%201294&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>B.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our next decision involving an antitrust challenge to a reverse
payment settlement of patent litigation came in
<i>Schering-Plough Corp. v. FTC</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d 1056</a> (11th
Cir. 2005). Schering, which held the patent for a drug called
K-Dur 20, settled lawsuits it had filed against two generic
drug manufacturers, Upsher-Smith Laboratories, Inc. and ESI
Lederle, Inc. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1058-60</a>. Schering's settlement
with Upsher had two main parts: (1) Upsher agreed not to enter
the K-Dur 20 market until five years before Schering's patent
expired, and (2) Schering paid Upsher more than $60 million to
license some of Upsher's other drug products. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id.
at 1059-60</a>. Schering's settlement with the other generic
manufacturer, ESI, also had two main parts: (1) ESI agreed not
to enter the K-Dur 20 market until almost three years before
Schering's patent expired; and (2) Schering paid ESI $5 million
in legal fees and $15 million to license some of ESI's other
drug products, plus another $10 million if ESI's generic drug
received FDA approval. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1060-61</a> &amp; n. 8.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC determined in an administrative proceeding that the
settlement agreements violated the FTC Act and the Sherman Act.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1058</a>. Although it did not expressly say that
reverse payment agreements are per se illegal, the FTC's order
nonetheless announced a rule prohibiting all reverse payment
settlements in which the generic company receives anything <span CLASS="page_no" data-cite="102 uspq 2d 1569" data-cite-type="ReporterOfDecisions" data-cite-pageno="1569" data-primary-citation="102 U.S.P.Q.2d 1561">[**1569]</span> of
value in exchange for deferring its research, development, or
entry to market. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1062</a>. The defendant drug
companies petitioned this Court to review the order, we did so,
and we vacated it. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1076</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We began our review of the FTC's order by reiterating what we
had said in <i>Valley Drug</i>: neither the rule of reason
nor the per se test is an appropriate way to analyze the
antitrust implications of a reverse payment settlement of
patent litigation.
<span CLASS="page_no" data-cite="677 f 3d 1310" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1310" data-primary-citation="677 F.3d 1298">[*1310]</span> 
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1065</a>. That traditional analysis is
inappropriate because one of the signatories to the settlement
holds a patent, and a patent conveys the right to "cripple
competition." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1066</a>. The proper analysis, we
explained, "requires an examination of: (1) the scope <span CLASS="page_no" data-cite="2012 bl 101301 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> of the
exclusionary potential of the patent; (2) the extent to which
the agreements exceed that scope; and (3) the resulting
anticompetitive effects." <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id</a>.</i> (citing <i>Valley</i>
<i>Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1312</a>). The essence of this three-prong
analysis is an evaluation of whether the settlement agreements
contain provisions that restrict competition beyond the scope
of the exclusionary potential of the patent. <i>Cf. United</i>
<i>States v. Singer Mfg. Co.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C5KM?jcsearch=374%20us%20174&amp;summary=yes#jcite">374 U.S. 174</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C5KM?jcsearch=374%20us%20174&amp;summary=yes#jcite">196-97</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C5KM?jcsearch=83%20supreme%20court%201773&amp;summary=yes#jcite">83 S.Ct. 1773</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C5KM?jcsearch=83%20supreme%20court%201773&amp;summary=yes#jcite">1785</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5C5KM?jcsearch=10%20l%20ed%202d%20823&amp;summary=yes#jcite">10 L.Ed.2d 823</a> (1963) ("[I]t is . . . well
settled that the possession of a valid patent or patents does
not give the patentee any exemption from the provisions of the
Sherman Act beyond the limits of the patent monopoly."); <i>In</i>
<i>re Tamoxifen Citrate Antitrust Litig.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X13U10Q003?jcsearch=466%20f%203d%20187&amp;summary=yes#jcite">466 F.3d 187</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X13U10Q003?jcsearch=466%20f%203d%20187&amp;summary=yes#jcite">213</a>
(2d Cir. 2006) ("[T]here is no injury to the market cognizable
under existing antitrust law, as long as competition is
restrained only within the scope of the patent.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After describing that analysis in <i>Schering-Plough</i>, we
defined the potential exclusionary scope of the K-Dur 20
patent, giving full force to the exclusionary rights it
potentially conveyed. Under the patent, Schering could exclude
both of the generic companies from the K-Dur 20 market.
<i>Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1066</a>. The patent also
gave Schering the "right to grant licenses, if it so chooses."
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1067</a>. Those exclusionary and licensing rights
existed until the patent expired on September 5, 2006, or until
the generic manufacturers "proved either that the . . . patent
was invalid or that their products . . . did not infringe
Schering's patent." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1066-67</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With the potential exclusionary scope of the patent defined in
<i>Schering-Plough</i>, we then evaluated whether the
settlements extended Schering's exclusionary rights beyond that
scope. That was simple to do. The settlement with Upsher
permitted that company to market its generic K-Dur 20 product
more than five years before the expiration of Schering's
patent, and the settlement with ESI allowed it to market its
generic product almost three years before the patent expired.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1068-71</a>. The settlements excluded competition
for a shorter period of time (five years less and three years
less) than the face of the patent allowed. For that reason, we
held that the reverse payment settlements did not impermissibly
extend Schering's patent monopoly.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our <i>Schering-Plough</i> decision also rejected the FTC's
argument that Schering had agreed to pay too much money to
settle the case and that the generic companies had agreed to
stay off the market for too long. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id. at 1073</a>. If
that were true, the FTC asserted, it meant that Schering must
have paid the generic companies not only to settle the
infringement lawsuit but also to obtain increased exclusionary
rights in the K-Dur 20 market. <i>See <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id</a>.</i> In other words,
the FTC claimed that Schering used the reverse payment
settlements not just to protect its legitimate bundle of patent
rights, but also to mask a "naked payment" to horizontal
competitors in order to expand the scope of its monopoly.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1070</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=1072&amp;summary=yes#jcite">1072</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We rejected the FTC's contention in part because it did not
take into account the underlying patent litigation, which was
"certain[] to be a bitter and prolonged process." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id.
at 1072</a>; <i>see also </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id. at 1075</a> ("[T]he size of the
payment . . . should not dictate the availability <span CLASS="page_no" data-cite="2012 bl 101301 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> of a
settlement remedy."). We emphasized that "[t]he general
<span CLASS="page_no" data-cite="677 f 3d 1311" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1311" data-primary-citation="677 F.3d 1298">[*1311]</span> 
policy of the law is to favor the settlement of
litigation," <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id. at 1072</a>, and reiterated that patent
litigation is costly and complex, <i>see </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id. at 1073-74</a>.
All three drug companies in <i>Schering-Plough</i> were
facing high risks and costs if they continued to litigate the
infringement action. <i>See </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">id. at 1075</a> (discussing the
costs of attorney fees, expert fees, and discovery expenses,
and noting the "caustic environment of patent litigation" that
may increase the "period of uncertainty" for patenting and
marketing new drugs). The agreements among the parties
reflected that high-stakes reality, so their settlements "fell
well within the protections of the [<span CLASS="page_no" data-cite="102 uspq 2d 1570" data-cite-type="ReporterOfDecisions" data-cite-pageno="1570" data-primary-citation="102 U.S.P.Q.2d 1561">[**1570]</span> K-Dur 20] patent, and were
therefore not illegal." <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id. at 1076</a>.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>C.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our third and most recent decision involving the antitrust
implications of reverse payment settlements is <i>Andrx</i>
<i>Pharmaceuticals, Inc. v. Elan Corp.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20f%203d%201227&amp;summary=yes#jcite">421 F.3d 1227</a> (11th
Cir. 2005). The district court in that case granted a patent
holder's motion for judgment on the pleadings, but we reversed
the judgment because the plaintiff had sufficiently pleaded an
antitrust claim. It had done so in two ways. First, the
complaint in <i>Andrx</i> alleged that the generic
manufacturer had agreed "to refrain from <i>ever</i>
marketing a generic" version of the patented drug. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20F.3d%201227&amp;summary=yes#jcite">Id.
at 1235</a> (emphasis added). If true, that meant the settlement
agreement blocked generic competition <i>after</i> the patent
expired, and in that way excluded competition beyond "the scope
of exclusion intended by the . . . patent." <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20F.3d%201227&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The other way the complaint in <i>Andrx</i> stated a
plausible antitrust claim was by alleging that the settlement
agreement allowed the generic company to retain its 180-day
exclusivity period of <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv) even
though that company had "no intention of marketing its generic
drug." <i>Andrx</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20f%203d%201227&amp;summary=yes#jcite">421 F.3d at 1231</a>. If true, that meant
the 180-day period, which begins to run "after the date of
first commercial marketing,"
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(B)(iv)(I)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(B)(iv)(I), would never be "trigger[ed],"
<i>Andrx</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20f%203d%201227&amp;summary=yes#jcite">421 F.3d at 1231</a>. As a result, the exclusivity
period would have acted like a cork in a bottle, blocking
<i>other</i> generic competition from pouring into the
market.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> By doing that, the settlement created
anticompetitive effects beyond the scope of the patent.
<i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20F.3d%201227&amp;summary=yes#jcite">Id. at 1235</a>; <i>see also </i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20F.3d%201227&amp;summary=yes#jcite">id. at 1231</a> ("[T]he
settlement agreement
<span CLASS="page_no" data-cite="677 f 3d 1312" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1312" data-primary-citation="677 F.3d 1298">[*1312]</span> 
had the effect of preventing <i>any</i> generic
competition in the . . . market and constituted a conspiracy to
restrain trade." (emphasis added)). For those reasons, we held
that the complaint in <i>Andrx</i> stated a plausible
antitrust claim. <i></i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20F.3d%201227&amp;summary=yes#jcite">Id. at 1236</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>IV.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our <i>Valley Drug, Schering-Plough</i>, and <i>Andrx</i>
decisions establish the rule that, absent sham litigation or
fraud in obtaining the patent, a reverse payment settlement is
immune from antitrust attack so long as its anticompetitive
effects fall within the scope of the exclusionary potential of
the patent.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> The issue in this case is whether, under that
test, the FTC's complaint states an antitrust claim by alleging
that Solvay was "not likely to prevail" in the underlying
infringement action against Watson, Par, and Paddock.
<span CLASS="page_no" data-cite="102 uspq 2d 1571" data-cite-type="ReporterOfDecisions" data-cite-pageno="1571" data-primary-citation="102 U.S.P.Q.2d 1561">[**1571]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC argues that its "not likely to prevail" allegation
sufficiently states an antitrust claim because a patent has
<i>no</i> exclusionary potential if <span CLASS="page_no" data-cite="2012 bl 101301 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> its holder was not likely
to win the underlying infringement suit. And if the patent has
no exclusionary potential, the FTC continues, then any reverse
payment settlement that excludes any competition from the
market necessarily exceeds the potential exclusionary scope of
the patent and must be seen as the patent holder's illegal
"`buying off of a serious threat to competition." Consistent
with that reasoning, the FTC urges us to adopt "a rule that an
exclusion payment is unlawful if, viewing the situation
objectively as of the time of the settlement, it is more likely
than not that the patent would not have blocked generic entry
earlier than the agreed-upon entry date." Under that rule, the
FTC's allegation that Solvay was "not likely to prevail" in the
patent litigation would state a plausible antitrust claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914047" href="#headnote_pq2-dec_914047">[1]</a> We decline the FTC's invitation and reject its argument. The
FTC's position equates a likely result (failure of an
infringement claim) with an actual result, but it is simply not
true that an infringement claim that is "likely" to fail
actually will fail. "Likely" means more likely than not, and
that includes a 51% chance of a result one way against a 49%
chance of a result the other way. <i>Cf. United States v.</i>
<i>Frazier</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XFPOD4?jcsearch=387%20f%203d%201244&amp;summary=yes#jcite">387 F.3d 1244</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XFPOD4?jcsearch=387%20f%203d%201244&amp;summary=yes#jcite">1280-81</a> (11th Cir. 2004) ("[I]t is
more likely than not &mdash; that is, there is more than a
fifty-percent chance &mdash; that [the event] would have
occurred."). Giving the word its plain meaning, as many as 49
out of 100 times that an infringement claim is "likely" to fail
it actually will succeed and keep the competitor out of the
market. Our decisions focus on
<span CLASS="page_no" data-cite="677 f 3d 1313" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1313" data-primary-citation="677 F.3d 1298">[*1313]</span> 
the potential exclusionary effect of the patent, not the
likely exclusionary effect. <i>See, e.g., Valley Drug</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1305</a>; <i>Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1066</a>;
<i>Andrx</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20f%203d%201227&amp;summary=yes#jcite">421 F.3d at 1235</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In few cases that are settled is the probability needle
pointing straight up. One side or the other almost always has a
better chance of prevailing, but a chance is only a chance, not
a certainty. Rational parties settle to cap the cost of
litigation and to avoid the chance of losing. Those motives
exist not only for the side that is likely to lose but also for
the side that is likely, but only likely, to win. A party
likely to win might not want to play the odds for the same
reason that one likely to survive a game of Russian roulette
might not want to take a turn. With four chambers of a
seven-chamber revolver unloaded, a party pulling the trigger is
likely (57% to 43%) to survive, but the undertaking is still
one that can lead to undertaking.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Patent litigation can also be a high stakes, spin-the-chambers,
all or nothing undertaking. <i>See Valley Drug</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1308</a>; <i>Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1075-76</a>. For the
company with a patented drug, it obviously makes sense to
settle the infringement action if it is "not likely to
prevail," even though that company may have a substantial (up
to 49%) chance of winning. On the other side of the settlement
equation is the generic drug company that is only "likely to
prevail" in the action; with a substantial (up to 49%) chance
of losing, that company also has a legitimate motive for
settling. When both sides of a dispute have a substantial
chance of winning and losing, especially when their chances may
<span CLASS="page_no" data-cite="2012 bl 101301 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> be 49% to 51%, it is reasonable for them to settle. That
companies with conflicting claims settle drug patent litigation
in these circumstances is not a violation of the antitrust
laws.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC argues in its brief that "Solvay's patent was
vulnerable," that it "knew that its patent was in trouble," and
that "its claims of infringement were very much in doubt."
Those arguments not only go beyond the allegations of the
complaint, which is all that we can consider in this appeal
from a Rule 12(b)(6) dismissal, but they also do little more
than reflect the reality of patent litigation and the risks it
presents to the patent holder. That reality and those risks are
precisely why a party is likely to choose to settle a patent
dispute even if it might well prevail. When hundreds of
millions of dollars of lost profits are at stake, "even a
patentee confident in the validity of its patent might pay a
potential infringer a substantial sum in settlement."
<i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1310</a>; <i>cf. In re</i>
<i>Ciprofloxacin Hydrochloride Antitrust Litig.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XANL80?jcsearch=261%20f%20supp%202d%20188&amp;summary=yes#jcite">261 F.Supp.2d 188</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XANL80?jcsearch=261%20f%20supp%202d%20188&amp;summary=yes#jcite">208</a> (E.D.N.Y. 2003) ("No matter how valid a
patent is &mdash; no matter how often it has been upheld in
other litigation or successfully reexamined &mdash; it is still
a gamble to place a technology case in the hands of a lay judge
or jury. Even the confident patent owner knows that the chances
of prevailing in patent litigation rarely exceed seventy
percent. Thus, there are risks involved even in that rare <span CLASS="page_no" data-cite="102 uspq 2d 1572" data-cite-type="ReporterOfDecisions" data-cite-pageno="1572" data-primary-citation="102 U.S.P.Q.2d 1561">[**1572]</span> case
with great prospects." (alterations and quotation marks
omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There are other reasons to reject the FTC's approach. It would
require an after-the-fact calculation of how "likely" a patent
holder was to succeed in a settled lawsuit if it had not been
settled. Predicting the future is precarious at best;
retroactively predicting from a past perspective a future that
never occurred is even more perilous. And it is too perilous an
enterprise to serve as a basis for antitrust liability and
treble damages. <i>See Valley</i>
<span CLASS="page_no" data-cite="677 f 3d 1314" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1314" data-primary-citation="677 F.3d 1298">[*1314]</span> 
<i>Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1308</a> ("Patent litigation is too
complex and the results too uncertain for parties to accurately
forecast whether enforcing the exclusionary right through
settlement will expose them to treble damages if the patent
immunity were destroyed by the mere invalidity of the
patent."); <i>cf. Whitmore v. Arkansas</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBS3?jcsearch=495%20us%20149&amp;summary=yes#jcite">495 U.S. 149</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBS3?jcsearch=495%20us%20149&amp;summary=yes#jcite">159-60</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBS3?jcsearch=110%20supreme%20court%201717&amp;summary=yes#jcite">110 S.Ct. 1717</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBS3?jcsearch=110%20supreme%20court%201717&amp;summary=yes#jcite">1725</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBS3?jcsearch=109%20l%20ed%202d%20135&amp;summary=yes#jcite">109 L.Ed.2d 135</a> (1990) ("It is
just not possible for a litigant to prove in advance that the
judicial system will lead to any particular result in his
case.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC's retrospective
predict-the-likely-outcome-that-never-came approach would also
impose heavy burdens on the parties and courts. It would
require, in the FTC's words, "viewing the situation objectively
as of the time of the settlement." In this case, assaying the
infringement claim "as of the time of settlement" would have
required mining through mountains of evidence &mdash; when the
lawsuit settled, more than 40 depositions had been taken and
one side alone had produced more than 350,000 pages of
documents. The settlement made that unnecessary, but the FTC's
approach would put that burden back on the parties and the
court, undo much of the benefit of settling patent litigation,
and discourage settlements. Our <span CLASS="page_no" data-cite="2012 bl 101301 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> legal system can ill afford
that. <i>See Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1075</a> ("There is
no question that settlements provide a number of private and
social benefits as opposed to the inveterate and costly effects
of litigation."); <i>see also Valley Drug</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1309</a> (noting "the important role played by settlement in the
enforcement of patent rights"); <i>cf. In re Tamoxifen</i>
<i>Citrate</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X13U10Q003?jcsearch=466%20f%203d%20187&amp;summary=yes#jcite">466 F.3d at 202</a> ("Where a case is complex and
expensive, and resolution of the case will benefit the public,
the public has a strong interest in settlement." (quotation
marks omitted)); <i>Flex-Foot, Inc. v. CRP, Inc.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X2A9GK?jcsearch=238%20f%203d%201362&amp;summary=yes#jcite">238 F.3d 1362</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X2A9GK?jcsearch=238%20f%203d%201362&amp;summary=yes#jcite">1368</a> (Fed. Cir. 2001) (noting "the important policy of
enforcing settlement agreements").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is also the fact that retrospective prediction, at least
in this type of case, is unlikely to be reliable. The FTC
itself has recognized as much in the past. In its order in the
<i>Schering-Plough</i> case, the full Commission explained
that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An after-the-fact inquiry by the Commission into the
  merits of the underlying litigation is not only
  unlikely to be particularly helpful, but also likely
  to be unreliable. As a general matter, tribunals
  decide patent issues in the context of a true
  adversary proceeding, and their opinions are informed
  by the arguments of opposing counsel. Once a case
  settles, however, the interests of the formerly
  contending parties are aligned. A generic competitor
  that has agreed to delay its entry no longer has an
  incentive to attack vigorously the validity of the
  patent in issue or a claim of infringement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>In re Schering-Plough Corp.</i>, No. <cite>9297</cite>,
<cite>2003 WL 22989651</cite>, at *22 (F.T.C. Dec. 8, 2003), <i>vacated by</i>
<i>Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d 1056</a>. For those reasons, the FTC
concluded that "it would not be necessary, practical, or
particularly useful . . . to embark on an inquiry into the
merits of the underlying patent dispute when resolving
antitrust issues in patent settlements." <i><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">Id</a>.</i> at *23.
The FTC was right then for the same reasons it is wrong now.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is another reason to reject the FTC's new approach.
Congress has given the United States Court of Appeals for the
Federal Circuit exclusive appellate jurisdiction over patent
cases. <i>See</i> <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1); <i>see also</i>
<i>Cardinal Chem. Co. v. Morton Int'l, Inc.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CCBB?jcsearch=508%20us%2083&amp;summary=yes#jcite">508 U.S. 83</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CCBB?jcsearch=508%20us%2083&amp;summary=yes#jcite">89</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CCBB?jcsearch=113%20supreme%20court%201967&amp;summary=yes#jcite">113 S.Ct. 1967</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CCBB?jcsearch=113%20supreme%20court%201967&amp;summary=yes#jcite">1971</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CCBB?jcsearch=124%20l%20ed%202d%201&amp;summary=yes#jcite">124 L.Ed.2d 1</a> (1993); <i>Christianson v.</i>
<i>Colt Indus. Operating Corp.</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBKE?jcsearch=486%20us%20800&amp;summary=yes#jcite">486 U.S. 800</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBKE?jcsearch=486%20us%20800&amp;summary=yes#jcite">807</a>,
<span CLASS="page_no" data-cite="677 f 3d 1315" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1315" data-primary-citation="677 F.3d 1298">[*1315]</span> 
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBKE?jcsearch=108%20supreme%20court%202166&amp;summary=yes#jcite">108 S.Ct. 2166</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBKE?jcsearch=108%20supreme%20court%202166&amp;summary=yes#jcite">2173</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X5CBKE?jcsearch=100%20l%20ed%202d%20811&amp;summary=yes#jcite">100 L.Ed.2d 811</a> (1988). This Court and the
other non-specialized circuit courts have no expertise or
experience in the area. We are ill-equipped to make a judgment
about the merits of a patent infringement claim, which is what
we would have to do in order to decide how likely the claim was
to prevail if it had been pursued to the end. The FTC's
approach is in tension with Congress' decision to have appeals
involving patent issues decided by the Federal Circuit.
<span CLASS="page_no" data-cite="102 uspq 2d 1573" data-cite-type="ReporterOfDecisions" data-cite-pageno="1573" data-primary-citation="102 U.S.P.Q.2d 1561">[**1573]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As we discussed at the beginning of this opinion, the FTC warns
that the alternative to its approach of looking back to decide
what the likely outcome of settled infringement claims would
have been is unacceptable. The alternative, according to the
FTC, will allow patent holders and potential competitors "to
forgo litigation over patent infringement and split up an
ongoing stream of monopoly profits, even in situations in which
it is evident that it is more likely than not that the patent
would be found invalid <span CLASS="page_no" data-cite="2012 bl 101301 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> or not infringed." The FTC believes
that, because drug prices will be higher in the absence of
competition, the profits generated by a patent holder's
monopoly will typically exceed the aggregated profits that all
companies individually would earn through competition. As a
result, a potential competitor can make more money by dropping
its patent challenge in return for a share of the holder's
monopoly profits than it can by continuing to attack an invalid
patent and bringing a less expensive version of the drug to
market before the patent expires.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FTC's ominous forecast discounts the reality that there
usually are many potential challengers to a patent, at least to
drug patents. If the patent actually is vulnerable, then
presumably other generic companies, which are not bound by the
first challenger's reverse payment settlement, will attempt to
enter the market and make their own challenges to the patent.
Blood in the water can lead to a feeding frenzy. Although a
patent holder may be able to escape the jaws of competition by
sharing monopoly profits with the first one or two generic
challengers, those profits will be eaten away as more and more
generic companies enter the waters by filing their own
paragraph IV certifications attacking the patent. <i>Cf.</i>
Herbert Hovenkamp, <i>Sensible Antitrust Rules for</i>
<i>Pharmaceutical Competition</i>, 39 U.S.F. L. Rev. 11, 25 (2004)
("In a world in which there are numerous firms willing and able
to enter the market, an exit payment to one particular
infringement defendant need not have significant
anticompetitive effects. If there is good reason for believing
the patent [is] invalid others will try the same thing.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In closing, it is worth emphasizing that what the FTC proposes
is that we attempt to decide how some other court in some other
case at some other time was likely to have resolved some other
claim if it had been pursued to judgment. If we did that we
would be deciding a patent case within an antitrust case about
the settlement of the patent case, a turducken task. Even if we
found that prospect palatable, we would be bound to follow the
simpler recipe for deciding these cases that is laid out in our
existing precedent. As we interpret that precedent, the FTC
loses this appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Bret Dickey, Jonathan Orszag &amp; Laura Tyson, <i>An</i>
<i>Economic Assessment of Patent Settlements in the Pharmaceutical</i>
<i>Industry</i>, 19 Annals Health L. 367, 369 &amp; n. 10
(2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> The FTC's brief offers this explanation of the economic
incentives involved:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to a study conducted by the FTC of the
  industry as a whole . . ., a branded manufacturer
  typically loses about 90 percent of its unit sales
  over the course of generic entry. While generic
  entrants gain that unit volume, they do not gain all
  the revenues lost by the branded manufacturer because,
  as generic competition sets in, the price falls, on
  average, to about 15 percent of what the branded
  manufacturer was charging. Thus, a branded
  manufacturer can expect that, if a drug is earning $1
  billion a year before generic entry, the manufacturer
  will only earn about $100 million a year once generic
  competition has matured, and all the generic companies
  put together will only earn about $135 million a year
  (90% x 15% x $1 billion), thus leaving approximately
  $765 million a year for the public through the
  benefits of competition. The parties have a strong
  economic incentive to avoid that result.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Appellant Br. 33-34 (footnotes omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Besins filed a separate lawsuit against Watson and
Paddock, but the outcome of that case is not relevant to this
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Two other sets of plaintiffs &mdash; direct and indirect
purchasers of AndroGel &mdash; joined the FTC in the district
court and made a variety of state law claims. None of those
plaintiffs joined the FTC in this appeal, and their claims are
not before us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> The analysis of whether a reverse payment agreement gives
rise to antitrust liability is the same for claims brought
under the Sherman Antitrust Act, which was involved in
<i>Valley Drug</i>, and under the Federal Trade Commission
Act, which is involved in this case. <i>See Schering-Plough</i>
<i>Corp. v. FTC</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d 1056</a> (11th Cir. 2005) (applying the
same antitrust analysis to Sherman Act and FTC Act
claims).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> In <i>Bonner v. City of Prichard</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X2NPGJ?jcsearch=661%20f%202d%201206&amp;summary=yes#jcite">661 F.2d 1206</a>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X2NPGJ?jcsearch=661%20f%202d%201206&amp;summary=yes#jcite">1209</a> (11th Cir. 1981) (en banc), we adopted as binding precedent
all decisions of the former Fifth Circuit handed down before
October 1, 1981. The <i>CMS</i> decision was issued on April
22, 1981.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> The traditional antitrust analysis consists of two tests:
the "per se" test and the "rule of reason" test. <i>See</i>
<i>Schering-Plough Corp. v. FTC</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d 1056</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">1064</a> (11th
Cir. 2005). Under the per se test, the challenged restraint
categorically violates the antitrust laws because it is "so
obviously anticompetitive, or so unlikely to be
pro-competitive, that [it] can be deemed to violate [the
antitrust laws] without much more than an examination of the
agreement itself and the relationships of the parties to the
agreement." <i>Valley Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1303</a>. Under the
rule of reason test, the legality of the challenged restraint
hinges upon whether it promotes or suppresses competition.
<i>See Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1064</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> The FTC's brief in this case places great weight on our
statement in <i>Schering-Plough</i> that a proper antitrust
analysis of reverse payment agreements needs to "evaluate the
<i>strength of the patent.</i>" <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20F.3d%201056&amp;summary=yes#jcite">402 F.3d at 1076</a> (emphasis
added). The FTC argues that evaluating the "strength of the
patent" means evaluating "the strength of the patent holder's
claims of validity and infringement, as objectively viewed at
the time of settlement.'' We disagree. When read in the context
of the facts and the reasoning of <i>Schering-Plough</i>, the
phrase "strength of the patent" refers to the potential
exclusionary scope of the patent &mdash; that is, the
exclusionary rights appearing on the patent's face and not the
underlying merits of the infringement claim. Nowhere in the
<i>Schering-Plough</i> opinion did we actually evaluate the
merits of the infringement claim when defining how much
competition the patent could potentially exclude from the
market.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> In 2003 Congress amended the statutory provisions
governing the 180-day exclusivity period to keep corks out of
bottles by providing that the first paragraph IV ANDA filer
forfeits its right of exclusivity if it fails to market a
generic drug within certain time periods. <i>See</i>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(5)(D)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(5)(D). A grandfather provision of that
amendment specified that the changes would not apply to
paragraph IV ANDAs filed before the date of enactment. Medicare
Prescription Drug, Improvement, and Modernization Act of 2003,
Pub.L. No. 108-713, <cite>&sect; 1102(b)(1)</cite>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/1?citation=117%20stat%202066&amp;summary=yes#jcite">117 Stat. 2066</a>. <i>See</i>
<i>generally Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc.</i>,
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d 1278</a>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">1284</a> n. 2 (Fed. Cir. 2008) (discussing the
amendment).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> There was no allegation in our first two decisions that
the patents were fraudulently obtained or that the litigation
giving rise to the settlement was a sham. <i>See Valley</i>
<i>Drug</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1307-09</a> &amp; nn. 19, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=21&amp;summary=yes#jcite">21</a>;
<i>Schering-Plough</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/XNSUKKII8BG0?jcsearch=402%20f%203d%201056&amp;summary=yes#jcite">402 F.3d at 1068</a>. The plaintiff in
our third decision did contend that there had been sham
litigation, but we rejected that contention as unfounded.
<i>See Andrx</i>, <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X12NUHM003?jcsearch=421%20f%203d%201227&amp;summary=yes#jcite">421 F.3d at 1233-34</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We stated in <i>Valley Drug</i> that: "[A]ppellees have
neither alleged nor asserted that the patent was procured by
fraud, that appellants knew the patent was invalid, that there
was no objective basis to believe that the patent was valid, or
any such similar allegations. We therefore are not called upon
to decide what the antitrust consequences of such circumstances
might be." <a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X6BE08?jcsearch=344%20f%203d%201294&amp;summary=yes#jcite">344 F.3d at 1307</a> n. 19. We make the same
observations about this case and limit our decision in the same
way. Although the FTC's complaint alleges that Solvay was "not
likely to prevail" in its infringement actions against Watson
and Par/Paddock, it does not contend that any of the three
companies knew that the patent was invalid or not infringed or
that there was no objective basis to believe the patent was
valid and infringed. Accordingly, we do not rule out the
possibility that sufficient allegations of any of those facts
would state a valid antitrust claim.
</p></div>
<!--BBLS DD 1705235906563-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HK3VM003/history">Direct History (13)</a>
</div>
<div class='sidebarItemLabel bold'>
Negative Direct History
</div>
<div class='bcite'>
<div class='sidebarItemLabel'>
Judgment reversed and case remanded by
</div>
<div class='citationAnalysisSideBarLabel'>
<a class="icon citation distinguished" href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1I27RGN" title="Distinguished"></a>
<a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1I27RGN">FTC v. Actavis, Inc., 133 S. Ct. 2223, 186 L. Ed. 2d 343, 106 U.S.P.Q.2d 1953 (2013)</a>
</div>
</div>

</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HK3VM003/analysis">Case Analysis (9)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HK3VM003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
9
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Health &amp; Medical</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/document/X1Q6LJQ24D82">10-12729 (11th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Antitrust &amp; Trade</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Contracts</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Tax &amp; Accounting</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/f0c4cbc06f0b4edece846c9eb719d2e0/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "f0c4cbc06f0b4edece846c9eb719d2e0";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY1109ea&previousPageId=&previousActivityInstanceId=ENTITY4e2d5c&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:52-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HK3VM003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY4e2d5c&previousPageId=&previousActivityInstanceId=ENTITY9555ab&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:49-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HK3VM003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HK3VM003";
$('#page_loader').show().spin();
JUDGE_IDS=["3028850"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
